{"id":2683,"date":"2026-06-16T22:36:41","date_gmt":"2026-06-16T22:36:41","guid":{"rendered":"https:\/\/glianomics.com\/blog\/?p=2683"},"modified":"2026-07-10T23:56:20","modified_gmt":"2026-07-10T23:56:20","slug":"osa-and-glp-1-drugs-what-the-surmount-osa-trial-actually-showed","status":"publish","type":"post","link":"https:\/\/glianomics.com\/blog\/osa-and-glp-1-drugs-what-the-surmount-osa-trial-actually-showed\/","title":{"rendered":"OSA and GLP-1 Drugs: What the SURMOUNT-OSA Trial Actually Showed"},"content":{"rendered":"\n

Part 3 of the OSA Trilogy<\/em><\/p>\n\n\n\n

You were prescribed a CPAP machine, brought it home, and tried to sleep with a mask strapped to your face. For a lot of people, that’s where the treatment story ends. Not because the machine doesn’t work, but because using it every night, long-term, is harder than the prescription makes it sound.<\/p>\n\n\n\n

That difficulty has real consequences. Real-world data consistently show that long-term CPAP adherence (defined as at least four hours per night on at least 70% of nights) sits at roughly 46 to 54% at 90 days to 12 months.[2] For those people, untreated sleep apnea continues doing what untreated sleep apnea does: disrupting oxygen delivery overnight, stressing the cardiovascular system, and fragmenting sleep in ways that show up in how you function during the day.<\/p>\n\n\n\n

Until June 2024, medicine’s answer to CPAP non-adherence was essentially: keep trying. There was no drug with solid clinical evidence behind it for reducing sleep apnea severity.<\/p>\n\n\n\n

That changed with the SURMOUNT-OSA trial.<\/p>\n\n\n\n

The treatment gap CPAP left behind<\/h2>\n\n\n\n

Obstructive sleep apnea (OSA) is measured using the apnea-hypopnea index (AHI): the number of breathing interruptions per hour during sleep. Moderate OSA begins at 15 events per hour. Severe OSA starts at 30.<\/p>\n\n\n\n

CPAP works by pressurising air through a mask to keep the airway open. It’s effective when it’s used consistently. The problem is that adherence is one of the most persistent challenges in sleep medicine. Many people with OSA don’t tolerate the mask, the noise, or the physical discomfort night after night. That leaves a significant group of patients with moderate-to-severe OSA and no functioning treatment.<\/p>\n\n\n\n

Until the SURMOUNT-OSA trial, there was no approved drug that had demonstrated a clinically meaningful reduction in AHI. That’s the gap the trial was built to address.<\/p>\n\n\n\n

What the SURMOUNT-OSA trial actually tested<\/h2>\n\n\n\n

SURMOUNT-OSA enrolled adults with moderate-to-severe OSA and obesity (BMI 30 or above) who were not adequately managed with PAP therapy. The trial ran as two parallel phase 3, double-blind, randomised controlled trials, both lasting 52 weeks.<\/p>\n\n\n\n

Trial 1 (n=234) enrolled people not currently using PAP therapy. Trial 2 (n=235) enrolled people who had been on PAP therapy and agreed to pause it for the duration of the trial. Both groups received either tirzepatide (up to 15mg weekly, maximum tolerated dose) or placebo.<\/p>\n\n\n\n

The primary outcome was change in AHI from baseline. At enrolment, the average AHI was 51.5 events per hour in Trial 1 and 49.5 events per hour in Trial 2, both solidly in the severe range.<\/p>\n\n\n\n

Tirzepatide is a dual agonist: it activates both GLP-1 and GIP receptors, the combination that drives more pronounced weight loss than GLP-1 receptor agonists alone. The hypothesis was that this weight loss, directed at people with obesity and severe OSA, would translate into a measurable reduction in breathing events during sleep.<\/p>\n\n\n\n

The numbers – and what they mean for how you sleep<\/h2>\n\n\n\n

In Trial 1, AHI fell by 25.3 events per hour in the tirzepatide group, compared to 5.3 events per hour in the placebo group. The estimated treatment difference was -20.0 events per hour (95% CI, -25.8 to -14.2; P<0.001).[1]<\/p>\n\n\n\n

In Trial 2, AHI fell by 29.3 events per hour on tirzepatide versus 5.5 on placebo, a treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9; P<0.001).[1]<\/p>\n\n\n\n

To put those numbers in context: the average trial participant started at around 50 breathing interruptions per hour. A reduction of 25 gets you to roughly 25, the upper end of the moderate range. The placebo group, averaging just a 5-event reduction, stayed in the severe range.<\/p>\n\n\n\n

\"fig1<\/figure>\n\n\n\n

For many people, moving from severe to moderate OSA means fewer oxygen drops overnight, lower cardiovascular strain, better sleep architecture, and noticeably less daytime fatigue. Secondary outcomes confirmed this: hypoxic burden, high-sensitivity C-reactive protein, systolic blood pressure, and patient-reported sleep quality all improved significantly with tirzepatide compared to placebo.[1] The trial was not designed or powered to measure cardiovascular events such as heart attack or stroke, so those outcomes remain an open question for future research.<\/p>\n\n\n\n

\"fig2<\/figure>\n\n\n\n

Who gets the most benefit and why Indian adults should pay attention<\/h2>\n\n\n\n

The trial data showed a consistent pattern. People with higher baseline AHI and higher BMI at enrolment tended to show larger absolute AHI reductions. The prevailing explanation is fat distribution. Tirzepatide reduces adiposity throughout the body. The obesity-OSA literature points to fat deposits around the upper airway as a key driver: tissue surrounding the tongue, soft palate, and throat that narrows the passage during sleep. Less of that tissue means more room for air. The SURMOUNT-OSA trial did not include upper airway imaging, so this connection remains inference rather than a confirmed finding.<\/p>\n\n\n\n

For Indian adults, the BMI threshold raises a specific problem. The SURMOUNT-OSA trial enrolled participants with BMI 30 or above, the conventional obesity threshold in Western guidelines. But for people of South Asian descent, metabolic risk and anatomical vulnerability to OSA appear at lower BMI values. Asian-adapted clinical thresholds used in India place overweight at BMI 23 and obesity at BMI 25. Revised 2024 guidelines have moved toward a staged obesity framework that incorporates waist circumference and functional criteria alongside BMI. But even using the simpler BMI threshold alone, many Indian adults with clinically significant OSA fall outside the trial’s enrolment criteria.<\/p>\n\n\n\n

Many Indian adults with moderate-to-severe OSA sit below the BMI 30 threshold used in the trial. That creates an eligibility gap that doesn’t reflect the clinical picture. Whether the trial’s effect sizes translate to lower-BMI Indian adults is a question the current data doesn’t answer. It’s a conversation worth having explicitly with your doctor if you’re in this group.<\/p>\n\n\n\n

What tirzepatide still does not replace<\/h2>\n\n\n\n

CPAP, when used consistently, remains the most established treatment for OSA. The SURMOUNT-OSA trial did not include a head-to-head comparison between tirzepatide and CPAP, so there is no data showing that tirzepatide performs better than CPAP. What the trial showed is that tirzepatide meaningfully reduces OSA severity on its own, which matters most for people who cannot or will not use CPAP.<\/p>\n\n\n\n

The 52-week trial window also leaves important questions open. What happens to AHI if someone stops tirzepatide? Does the airway narrow again as weight returns? These are not answered yet, and the absence of long-term data beyond one year is a real limitation.<\/p>\n\n\n\n

Access and cost are not minor considerations for Indian adults. In December 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity, for use in combination with a reduced-calorie diet and increased physical activity. It was the first drug approved for this indication. Regulatory approval in India for this specific use has not followed at the same pace, and the out-of-pocket cost of tirzepatide remains substantial.<\/p>\n\n\n\n

Here’s what the trial actually showed: for people with moderate-to-severe OSA who are also managing obesity and cannot tolerate CPAP, it’s the first drug with solid clinical evidence behind it. That’s the gap it fills. It doesn’t close the treatment conversation. It adds a real option where there wasn’t one.<\/p>\n\n\n\n

\n\n\n\n

The SURMOUNT-OSA trial matters because it’s the first time a drug has shown this scale of effect on OSA severity in a rigorous, large, controlled trial. The effect is real. So are the limits of the data. If you have OSA and have been struggling with CPAP, the trial results give your next conversation with your doctor a clearer foundation and a set of questions worth asking.<\/p>\n\n\n\n

This is Part 3 of the OSA Trilogy. Part 1 covers OSA prevalence in Indian adults. Part 2 examines what repeated hypoxic stress does to metabolic markers, the mechanism that makes untreated OSA a metabolic disease, not just a sleep problem.<\/p>\n\n\n\n

You can also explore how GLP-1 medications affect other body systems beyond weight loss in The Evidence-Based Extra Benefits of GLP-1 Medication<\/a><\/mark>, and a broader look at GLP-1 and sleep in GLP-1 Agonist and Sleep Disorders: How This Drug Has Changed the Treatment Protocol<\/mark><\/a>.<\/p>\n\n\n\n

\n
\n

Join the Field Notes<\/h2>

Metabolic Field Notes tracks the evidence as it develops, without protocol-pushing and without hype. If evidence-aware, translational science is useful to you, join the Field Notes.<\/p><\/div>\n<\/div>\n\n\n\n

\n
Email<\/div><\/div>\n
<\/div>
<\/div>